title: Coexistence of EGFR mutation and ALK translocation in NSCLC: literature review and case report of response to gefitinib.
abstract: The coexistence of EGFR and ALK-EML4 gene mutations represents a rare event (about 1%) in patients with non small cell lung cancer (NSCLC) and the few cases described in the literature have all been treated by different methods. We present the case of a 52-year-old woman with adenocarcinoma of the lung whose tumor had this double genetic aberration. The patient was immediately treated with gefitinib because the tumor was judged inoperable, but after two months she obtained an important clinical remission and was submitted to radical surgery. She is currently undergoing adjuvant treatment with gefitinib. A review of the literature on this double genetic aberration highlighted that further research is needed to define the best therapeutic approach.
authors.affiliation: U.O. Oncologia, Ospedale Infermi Rimini, 2 Settembrini Street, Rimini, Italy. carlotta.santelmo@alice.it
authors.forename: C
authors.initials: C
authors.lastname: Santelmo
authors.forename: A
authors.initials: A
authors.lastname: Ravaioli
authors.forename: E
authors.initials: E
authors.lastname: Barzotti
authors.forename: M
authors.initials: M
authors.lastname: Papi
authors.forename: B
authors.initials: B
authors.lastname: Poggi
authors.forename: F
authors.initials: F
authors.lastname: Drudi
authors.forename: M
authors.initials: M
authors.lastname: Mangianti
authors.forename: M
authors.initials: M
authors.lastname: Salvi
authors.forename: L
authors.initials: L
authors.lastname: Crinò
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy / Q000201:enzymology / Q000235:genetics / Q000378:metabolism; D000077192:Adenocarcinoma of Lung; D000077548:Anaplastic Lymphoma Kinase; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics / Q000378:metabolism; D018797:Cell Cycle Proteins / Q000235:genetics; D066246:ErbB Receptors / Q000235:genetics*; D005260:Female; D000077156:Gefitinib; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics / Q000378:metabolism; D008869:Microtubule-Associated Proteins / Q000235:genetics; D008875:Middle Aged; D009154:Mutation; D011799:Quinazolines / Q000627:therapeutic use*; D020794:Receptor Protein-Tyrosine Kinases / Q000235:genetics*; D012697:Serine Endopeptidases / Q000235:genetics
chemical_list: D018797:Cell Cycle Proteins; D008869:Microtubule-Associated Proteins; D011799:Quinazolines; C000626173:ALK protein, human; D000077548:Anaplastic Lymphoma Kinase; C512478:EGFR protein, human; D066246:ErbB Receptors; D020794:Receptor Protein-Tyrosine Kinases; C415585:EML4 protein, human; D012697:Serine Endopeptidases; D000077156:Gefitinib
keywords: ALK translocation; Double mutation; EGFR mutation; Gefitinib; Neoadjuvant chemotherapy; Non small cell lung cancer